Overview

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

Bayer
Bristol-Myers Squibb

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins
Nivolumab